AMLN (DIABETES DRUGS) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AMLN (DIABETES DRUGS)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: arnie h who wrote (1114)	2/13/1998 12:09:00 AM
From: D.Right	Read Replies (3) of 2173

Dear Arnie: It is definitely a good thing for us to know that number. On theory, those subgroups should have a higher percentage (more than 75%) than the whole trial population to continue using pramlintide as they benefit the most. However I think it is just impossible to find out. The only people who would know are the AMLN people. But as you pointed out the number was too small for statistics analysis then, it is still to small to do that now. Also, those 20+23 patients were on fixed doses of insulin then but they may not on fixed doses of insulin now. One way or the other, the number won't be that reliable, so why give it. Still, it is worth trying by just calling the AMLN IR people. Good luck. Let the thread know if it happens, thanks. D.Right

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next